Research Paper Volume 16, Issue 5 pp 4841—4861
HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma
Figure 7. Combination of Hoxc9 inhibition and PD-1 blockade enhanced the tumor growth and improved CD8+ T cell infiltration. (A) Diagram of in vivo experiment design. (B) Tumor growth curves of different groups. (C, D) More effective CD8+ T cells were observed in Hoxc9 knockdown groups compared to control groups under IgG/PD-1 blockade. (*P<0.05, **P<0.01, ***P<0.001).